#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

INTERDISCIPLINARY COMMUNICATION BETWEEN UROLOGIST AND ONCOLOGIST AND ITS IMPLEMENTATION IN HORMONE REFRACTORY PROSTATE CANCER


Authors: Marko Babjuk 1;  Petr Brabec 2;  Ladislav;  Dušek 2;  Tomáš Pavlík 2;  Jindřich Fínek 3;  Dalibor Pacík 4;  Luboš Petruželka 5;  Michaela Matoušková 6
Authors‘ workplace: Urologická klinika 1. LF UK a VFN, Praha 1;  IBA, Masarykova univerzita, Brno 2;  Radioterapeutické a onkologické oddělení FN, Plzeň 3;  Urologická klinika, FN Bohunice, Masarykova Univerzita, Brno 4;  Onkologická klinika 1. LF UK a VFN, Praha 5;  Urocentrum Praha 6
Published in: Ces Urol 2009; 13(2): 149-160
Category: Review article

Overview

Professional communication among physicians is currently of growing importance, namely in fields that stand in the centre of interest of two or more medical disciplines. It holds also for cancer diagnoses that are associated with urogenital system. Using advanced stages of prostate cancer as example, we introduce here technological and operational background of newly initiated project UJO („Urology Joins Oncology“). Th e project strives to facilitate collaboration between urologists and oncologists using modern ICTs. Non-interventional clinical registry is based on fully parametric database equipped by functional on-line system, centralized data management and electronic support of communication. Th e registry is aimed to follow diagnostics and therapy of HRPC. Optimized data set allows to assess the risk and prognostic factors as well as reference monitoring of therapeutic outcomes. Project contributes to the implementation of electronic patient’s documentation in this field. Detailed information and reporting is available in project portal http://ujo.registry.cz.

Key words:
epidemiology, hormone refractory prostate cancer, clinical registry, non-interventional monitoring.


Sources

1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502–1512.

2. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513–1520.

3. Ústav zdravotnických informací a statistiky ČR, Novotvary (Cancer Incidence in the Czech Republic); vydáváno každoročně, poslední vydání: rok 2005. ISBN 978-80-7280-723-9, dostupné z http://www.uzis.cz.

4. Dušek L, Mužík J, Kubásek M, Koptíková J, Žaloudík J, Vyzula R. Epidemiologie zhoubných nádorů v České republice [online]. Masarykova univerzita, [2005] [cit. 2008-8-26]. Dostupný z WWW: http://www.svod.cz. Verze 7.0 [2007], ISSN 1802-8861.

5. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5. version 2.0. Lyon: IARCPress 2004; http://www-dep.iarc.fr

Labels
Paediatric urologist Nephrology Urology
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#